PFS Clinical Revenue and Competitors
Estimated Revenue & Valuation
- PFS Clinical's estimated annual revenue is currently $2.6M per year.
- PFS Clinical's estimated revenue per employee is $81,600
Employee Data
- PFS Clinical has 32 Employees.
- PFS Clinical grew their employee count by -33% last year.
PFS Clinical's People
Name | Title | Email/Phone |
---|---|---|
1 | Manager, Quality and Development | Reveal Email/Phone |
2 | Senior Clinical Research Analyst | Reveal Email/Phone |
PFS Clinical Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1090M | 6130 | 8% | $38.4M | $6.3B |
What Is PFS Clinical?
PFS Clinical provides customizable solutions to the unique challenges inherent to clinical research. We've built a team of experts in critical areas of research operations based on a thorough understanding of the needs and challenges of this industry. We serve all types of research institutions with a flexible model that allows us to efficiently match your needs with our expertise. Our core services include (but are not limited to) coverage analysis, budget development/negotiations, contract development/negotiations, training, and CTMS support.
keywords:N/AN/A
Total Funding
32
Number of Employees
$2.6M
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
PFS Clinical News
The PFS rate was 60% in the rucaparib arm and 100% in the placebo arm. ... in Palo Alto, Calif., told Clinical Oncology News.
An updated analysis of the primary endpoint (PFS) and two secondary ... placebo-controlled Phase 3 clinical trial (NCT03924986) designed to...
Pfizer's Lorbrena shows PFS improvement in Phase III lung cancer trial ... advanced lung cancer patients in Phase III CROWN clinical trial.
Last week was a busy week for clinical trial results. .... least 18 patients with the primary endpoint progression-free survival (PFS) at six months.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.4M | 32 | 14% | N/A |
#2 | $8.4M | 32 | 0% | N/A |
#3 | $7.4M | 32 | -6% | N/A |
#4 | $6.3M | 32 | -6% | N/A |
#5 | $5.6M | 32 | -37% | N/A |